Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2.

Publication Type	Academic Article
Authors	Sondhi D, Kaminsky S, Hackett N, Pagovich O, Rosenberg J, De B, Chen A, Van de Graaf B, Mezey J, Mammen G, Mancenido D, Xu F, Kosofsky B, Yohay K, Worgall S, Kaner R, Souwedaine M, Greenwald B, Kaplitt M, Dyke J, Ballon D, Heier L, Kiss S, Crystal R
Journal	Sci Transl Med
Volume	12
Issue	572
Date Published	12/02/2020
ISSN	1946-6242
Keywords	Dependovirus, Neuronal Ceroid-Lipofuscinoses
Abstract	Late infantile Batten disease (CLN2 disease) is an autosomal recessive, neurodegenerative lysosomal storage disease caused by mutations in the CLN2 gene encoding tripeptidyl peptidase 1 (TPP1). We tested intraparenchymal delivery of AAVrh.10hCLN2, a nonhuman serotype rh.10 adeno-associated virus vector encoding human CLN2, in a nonrandomized trial consisting of two arms assessed over 18 months: AAVrh.10hCLN2-treated cohort of 8 children with mild to moderate disease and an untreated, Weill Cornell natural history cohort consisting of 12 children. The treated cohort was also compared to an untreated European natural history cohort of CLN2 disease. The vector was administered through six burr holes directly to 12 sites in the brain without immunosuppression. In an additional safety assessment under a separate protocol, five children with severe CLN2 disease were treated with AAVrh.10hCLN2. The therapy was associated with a variety of expected adverse events, none causing long-term disability. Induction of systemic anti-AAVrh.10 immunity was mild. After therapy, the treated cohort had a 1.3- to 2.6-fold increase in cerebral spinal fluid TPP1. There was a slower loss of gray matter volume in four of seven children by MRI and a 42.4 and 47.5% reduction in the rate of decline of motor and language function, compared to Weill Cornell natural history cohort (P < 0.04) and European natural history cohort (P < 0.0001), respectively. Intraparenchymal brain administration of AAVrh.10hCLN2 slowed the progression of disease in children with CLN2 disease. However, improvements in vector design and delivery strategies will be necessary to halt disease progression using gene therapy.
DOI	10.1126/scitranslmed.abb5413
PubMed ID	33268510
PubMed Central ID	PMC8056991